GlassScriptPhysician profile
Steven Pearce
NPI 1154042901
$3,525.69
in general payments reported to CMS, 2019-2025
20 companies · $1,904 in 2025
The $1,904 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $404 · 2024: $1,218 · 2025: $1,904.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,195 · Travel and Lodging: $330.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,195.24 |
| Travel and Lodging | $330.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $844.12 | 2023-2025 | Watchman Access System, Watchman Flx |
| Novartis Pharmaceuticals Corporation | $644.15 | 2023-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $297.43 | 2024-2025 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $287.37 | 2023-2025 | Camzyos |
| Atricure, INC. | $257.47 | 2025 | Epi-Sense Guided Coagulation System With Visitrax, Atriclip Laa Exclusion System |
| Actelion Pharmaceuticals US, INC. | $257.06 | 2024-2025 | Opsumit, Uptravi, Opsynvi |
| Merck Sharp & Dohme LLC | $211.83 | 2023-2025 | Verquvo, Capvaxive |
| Amgen INC. | $134.21 | 2024-2025 | Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $115.01 | 2023-2025 | Jardiance |
| Scpharmaceuticals INC. | $84.54 | 2024-2025 | |
| Cardiva Medical, INC. | $70.84 | 2024-2025 | Cardiva Vascade Mvp Vvcs 6-12f |
| Alnylam Pharmaceuticals INC. | $58.86 | 2023-2025 | Onpattro |
| Biotronik INC. | $54.59 | 2024-2025 | Acticor 7 Vr-T Dx |
| Cvrx, INC. | $47.87 | 2024-2025 | Barostim Neo System |
| Janssen Pharmaceuticals, INC | $38.57 | 2023-2024 | Xarelto |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $36.70 | 2024 | Micra, Linq II |
| Sanofi-Aventis U.S. LLC | $25.11 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $23.05 | 2024 | Farxiga |
| Lilly USA, LLC | $22.39 | 2025 | Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $14.52 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Pearce listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.